Genmab (CPSE:GMAB) - Cotización, noticias y análisis

Resumen de acción GMAB

Genmab A/S desarrolla terapias de anticuerpos para el tratamiento del cáncer y otras enfermedades, principalmente en Dinamarca.

Acerca de la empresa

GMAB fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	4/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Recompensas

Cotiza un 70.8% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 21.65%

Cotiza a buen valor en comparación con empresas similares e industria

Análisis de riesgos

Venta significativa por parte de personas con información privilegiada en los últimos 3 meses

Competidores de Genmab A/S

Bavarian Nordic

CPSE:BAVA

kr.12.0b

ALK-Abelló

CPSE:ALK B

kr.28.9b

H. Lundbeck

CPSE:HLUN B

kr.32.9b

Neurocrine Biosciences

NasdaqGS:NBIX

US$13.8b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Genmab
Historical stock prices
Current Share Price	kr.1,956.50
52 Week High	kr.2,939.00
52 Week Low	kr.1,825.00
Beta	0.78
1 Month Change	-6.12%
3 Month Change	1.85%
1 Year Change	-29.52%
3 Year Change	-12.07%
5 Year Change	78.11%
Change since IPO	739.70%

Noticias y actualizaciones recientes

Genmab A/S' (CPH:GMAB) Price In Tune With Earnings

Apr 02

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Mar 07

Recent updates

Genmab A/S' (CPH:GMAB) Price In Tune With Earnings

Apr 02

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Mar 07

Rentabilidad de los accionistas

	GMAB	DK Biotechs	Mercado DK
7D	-2.6%	-1.0%	0.3%
1Y	-29.5%	-14.6%	26.9%

Rentabilidad vs. Industria: GMAB obtuvo unos resultados inferiores a los del sector Danish Biotechs , que el año pasado arrojó un rendimiento del -15.6%.

Rentabilidad vs. Mercado: GMAB obtuvo unos resultados inferiores a los del mercado Danish, que fue del 26.5% el año pasado.

Volatilidad de los precios

Is GMAB's price volatile compared to industry and market?
GMAB volatility
GMAB Average Weekly Movement	4.2%
Biotechs Industry Average Movement	7.3%
Market Average Movement	4.6%
10% most volatile stocks in DK Market	9.6%
10% least volatile stocks in DK Market	2.9%

Precio estable de las acciones: GMAB no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de GMAB (4%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1999	2,204	Jan G.J. de Winkel	www.genmab.com

Genmab A/S desarrolla anticuerpos terapéuticos para el tratamiento del cáncer y otras enfermedades, principalmente en Dinamarca. La empresa comercializa DARZALEX, un anticuerpo monoclonal humano para el tratamiento de pacientes con mieloma múltiple (MM); teprotumumab para el tratamiento de la enfermedad ocular tiroidea; y Amivantamab para el cáncer gástrico o esofágico avanzado o metastásico y el CPNM. Sus productos incluyen daratumumab para tratar MM, cánceres de la sangre no MM y amiloidosis AL; GEN1047; tisotumab vedotin para tratar cánceres de cuello uterino, ovario y sólidos; DuoBody-PD-L1x4-1BB, y DuoBody-CD40x4-1BB para tratar tumores sólidos; Epcoritamab para el linfoma difuso de células B grandes y la leucemia linfocítica crónica en recaída o refractarios; y HexaBody-CD38 y GEN3017 para el tratamiento de neoplasias hematológicas.

Resumen de fundamentos de Genmab A/S

¿Cómo se comparan los beneficios e ingresos de Genmab con su capitalización de mercado?
Estadísticas fundamentales de GMAB
Capitalización bursátil	kr.126.52b
Beneficios(TTM)	kr.4.35b
Ingresos (TTM)	kr.16.47b

29.1x

Ratio precio-beneficio (PE)

7.7x

Ratio precio-ventas (PS)

¿Está GMAB sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de GMAB
Ingresos	kr.16.47b
Coste de los ingresos	kr.226.00m
Beneficio bruto	kr.16.25b
Otros gastos	kr.11.90b
Beneficios	kr.4.35b

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

May 02, 2024

Beneficios por acción (BPA)	67.30
Margen bruto	98.63%
Margen de beneficio neto	26.42%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado GMAB a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción GMAB

Recompensas

Análisis de riesgos

Competidores de Genmab A/S

CPSE:BAVA

kr.12.0b

CPSE:ALK B

kr.28.9b

CPSE:HLUN B

kr.32.9b

NasdaqGS:NBIX

US$13.8b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S' (CPH:GMAB) Price In Tune With Earnings

Genmab A/S Announces Executive Changes

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Recent updates

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S' (CPH:GMAB) Price In Tune With Earnings

Genmab A/S Announces Executive Changes

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Executive VP & CFO recently sold kr.22m worth of stock

Executive VP & CFO exercised options to buy kr.22m worth of stock.

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab's (CPH:GMAB) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings: EPS misses analyst expectations

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Is Genmab A/S (CPH:GMAB) Trading At A 50% Discount?

Genmab A/S Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: kr.32.60 (vs kr.39.55 in 3Q 2022)

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Investor sentiment deteriorates as stock falls 16%

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Is Now The Time To Put Genmab (CPH:GMAB) On Your Watchlist?

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

Co-Founder recently sold kr.58m worth of stock

Is There An Opportunity With Genmab A/S' (CPH:GMAB) 44% Undervaluation?

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

First quarter 2023 earnings released: EPS: kr.3.46 (vs kr.7.10 in 1Q 2022)

Independent Chairman of the Board recently bought kr.796k worth of stock

With EPS Growth And More, Genmab (CPH:GMAB) Makes An Interesting Case

Genmab A/S (CPH:GMAB) Shares Could Be 50% Below Their Intrinsic Value Estimate

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Here's Why We Think Genmab (CPH:GMAB) Is Well Worth Watching

Co-Founder recently sold kr.57m worth of stock

Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Are Investors Undervaluing Genmab A/S (CPH:GMAB) By 46%?

Genmab A/S Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (Bla) for Epcoritamab (Duobody®-Cd3xcd20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (Lbcl)

Consensus EPS estimates increase by 45%

Third quarter 2022 earnings released: EPS: kr.39.55 (vs kr.13.61 in 3Q 2021)

Genmab Provides Earnings Guidance for Year 2022

Genmab A/S Submits Biologics License Application to the U.S. Food and Drug Administration

Do Genmab's (CPH:GMAB) Earnings Warrant Your Attention?

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Genmab A/S Revises Earnings Guidance for the Year 2022

Genmab A/S Submits Biologics License Application to U.S. Food and Drug Administration for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Investor sentiment improved over the past week